Vesleteplirsen

Sarepta Therapeutics has submitted SRP-9001 (delandistrogene moxeparvovec) to the FDA for accelerated approval to treat ambulatory Duchenne muscular dystrophy (DMD) patients.

Sarepta Therapeutics has discontinued the development of vesleteplirsen, an experimental exon 51-skipping therapy.

Sarepta Therapeutics discontinues the development of vesleteplirsen (SRP-5051), an exon-skipping antisense oligonucleotide (ASO) for Duchenne muscular dystrophy (DMD).

Sarepta Therapeutics halts development of vesleteplirsen (SRP-5051), a more potent follow-up to Exondys 51 for Duchenne muscular dystrophy (DMD).

Sarepta Therapeutics discontinues vesleteplirsen (SRP-5051) development for Duchenne muscular dystrophy due to safety concerns and FDA feedback.